No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission.

Dipartimento Ematologia e Oncologia Pediatrica, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) G. Gaslini, Largo G. Gaslini 5, Genoa, Italy.
Blood (Impact Factor: 9.78). 12/2011; 118(25):6683-90. DOI: 10.1182/blood-2011-05-354233
Source: PubMed

ABSTRACT Acute lymphoblastic leukemia (ALL) in second complete remission is one of the most common indications for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients. We compared the outcome after HCST of adolescents, aged 14 to 18 years, with that of children (ie, patients < 14 years of age). Enrolled in the study were 395 patients given the allograft between January 1990 and December 2007; both children (334) and adolescents (61) were transplanted in the same pediatric institutions. All patients received a myeloablative regimen that included total body irradiation in the majority of them. The donor was an HLA-identical sibling for 199 patients and an unrelated volunteer in the remaining 196 patients. Children and adolescents had a comparable cumulative incidence of transplantation-related mortality, disease recurrence, and of both acute and chronic graft-versus-host disease. The 10-year probability of overall survival and event-free survival for the whole cohort of patients were 57% (95% confidence interval, 52%-62%) and 54% (95% confidence interval, 49%-59%), respectively, with no difference between children and adolescents. This study documents that adolescents with ALL in second complete remission given HSCT in pediatric centers have an outcome that does not differ from that of patients younger than 14 years of age.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Sirolimus, an mTOR inhibitor, has activity against human ALL in xenograft models and efficacy in preventing acute GVHD (aGVHD). We tested whether addition of sirolimus to GVHD prophylaxis of children undergoing transplantation for ALL would decrease aGVHD and relapse, thus improving survival. Patients were randomized to tacrolimus/methotrexate (standard) or tacrolimus/methotrexate/sirolimus (experimental). The study met futility rules for survival after enrolling 146 of 259 planned patients. The proportion of patients with Grade II-IV aGVHD was 31% vs. 18% in the standard vs. the experimental arm (p=0.04), however, grade III-IV aGVHD was not statistically different (13% vs. 10%, p=0.28). Rates of veno-occlusive disease and thrombotic microangiopathy were lower in the non-sirolimus arm (9% vs. 21% VOD, p=0.05; 1% vs. 10% TMA, p=0.06). At 2 years, EFS and OS were 56% vs 46%, and 65% vs 55% in the standard and experimental arms, respectively (p= 0.28 and 0.23). Multivariate analysis showed increased relapse risk in children with ≥0.1% MRD pre-transplant, and decreased risk in patients with grades I-III aGVHD (p=0.04). Grades I-III aGVHD were associated with improved EFS (p=0.02), while grade IV aGVHD and extramedullary disease at initial diagnosis led to inferior OS. Although addition of sirolimus decreased aGVHD, survival was not improved. The study is registered with ( Identifier: NCT00382109).
    Blood 02/2014; · 9.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To review and summarize the available evidence on factors predicting prognosis of children with relapsed acute lymphoblastic leukemia (ALL) and on the currently used treatment strategies, as well as on the most promising and innovative molecular or cellular therapies. Relapse still represents the most common cause of treatment failure, occurring in approximately 15-20% of childhood ALL. Risk-oriented standard salvage regimens are mostly based on combinations of the same agents incorporated in frontline therapies. Allogeneic hematopoietic stem cell transplantation (HSCT) is largely employed as postremission therapy, being superior to chemotherapy in high-risk patients. With conventional therapies including HSCT, 40-50% of children with relapsed ALL can be rescued. Thus, innovative approaches are needed to further improve the outcome of patients, especially when carrying poor prognostic factors. The last decade has witnessed the development of novel agents, including nucleoside analogues, anti-CD22 monoclonal antibodies and bi-specific, anti-CD3/CD19 antibodies, together with new formulations of existing chemotherapeutic agents and targeted molecules, such as tyrosine kinase inhibitors and FLT3 inhibitors. A significant proportion of children with relapsed ALL are salvaged by risk-oriented therapies. Novel agents should be integrated into combination regimens with the aim of further improving outcome of patients.
    Current opinion in oncology 09/2013; · 4.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Data on outcomes of allogeneic transplantation in children with Down syndrome and acute myelogenous leukemia (DS-AML) are scarce and conflicting. Early reports stress treatment-related mortality as the main barrier; a recent case series points to post-transplant relapse. DESIGN: and methods. We reviewed outcome data for 28 patients with DS-AML reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) between 2000 and 2009 and performed a first matched-pair analysis of 21 patients with DS-AML and 80 non-DS AML controls. RESULTS: The median age at transplantation for DS-AML was 3 years and almost half of the cohort was in second remission. The 3-year probability of overall survival was only 19%. In multivariate analysis, adjusting for interval from diagnosis to transplantation, risks of relapse (HR 2.84, p<0.001; 62% vs. 37%) and transplant-related mortality (HR 2.52, p=0.04; 24% vs. 15%) were significantly higher for DS-AML compared to non-DS AML. Overall mortality risk (HR 2.86, p<0.001; 21% vs. 52%) was significantly higher for DS-AML. CONCLUSIONS: Both transplant-related mortality and relapse contribute to higher mortality. Excess mortality in DS-AML patients can only effectively be addressed through an international multi-center effort to pilot strategies aimed at lowering both transplant-related mortality and relapse risks.
    Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 03/2013; · 3.15 Impact Factor